These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
869 related articles for article (PubMed ID: 28746345)
1. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest. Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345 [TBL] [Abstract][Full Text] [Related]
2. Calotropin from Asclepias curasavica induces cell cycle arrest and apoptosis in cisplatin-resistant lung cancer cells. Mo EP; Zhang RR; Xu J; Zhang H; Wang XX; Tan QT; Liu FL; Jiang RW; Cai SH Biochem Biophys Res Commun; 2016 Sep; 478(2):710-5. PubMed ID: 27498029 [TBL] [Abstract][Full Text] [Related]
3. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer. Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469 [TBL] [Abstract][Full Text] [Related]
4. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest. Lundholm L; Hååg P; Zong D; Juntti T; Mörk B; Lewensohn R; Viktorsson K Cell Death Dis; 2013 Jan; 4(1):e478. PubMed ID: 23370278 [TBL] [Abstract][Full Text] [Related]
5. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation. Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736 [TBL] [Abstract][Full Text] [Related]
6. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells. Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014 [TBL] [Abstract][Full Text] [Related]
7. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells. Shin DY; Sung Kang H; Kim GY; Kim WJ; Yoo YH; Choi YH Biomed Pharmacother; 2013 May; 67(4):305-11. PubMed ID: 23582784 [TBL] [Abstract][Full Text] [Related]
8. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway. Xia Y; He Z; Liu B; Wang P; Chen Y Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239 [TBL] [Abstract][Full Text] [Related]
9. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells. Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719 [TBL] [Abstract][Full Text] [Related]
10. A novel quinazoline-based analog induces G2/M cell cycle arrest and apoptosis in human A549 lung cancer cells via a ROS-dependent mechanism. Shi H; Li Y; Ren X; Zhang Y; Yang Z; Qi C Biochem Biophys Res Commun; 2017 Apr; 486(2):314-320. PubMed ID: 28302490 [TBL] [Abstract][Full Text] [Related]
11. Cisplatin resistance in human lung cancer cells is linked with dysregulation of cell cycle associated proteins. Horibe S; Matsuda A; Tanahashi T; Inoue J; Kawauchi S; Mizuno S; Ueno M; Takahashi K; Maeda Y; Maegouchi T; Murakami Y; Yumoto R; Nagai J; Takano M Life Sci; 2015 Mar; 124():31-40. PubMed ID: 25625243 [TBL] [Abstract][Full Text] [Related]
12. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Galluzzi L; Morselli E; Vitale I; Kepp O; Senovilla L; Criollo A; Servant N; Paccard C; Hupé P; Robert T; Ripoche H; Lazar V; Harel-Bellan A; Dessen P; Barillot E; Kroemer G Cancer Res; 2010 Mar; 70(5):1793-803. PubMed ID: 20145152 [TBL] [Abstract][Full Text] [Related]
13. Theaflavin-3, 3'-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells. Tu Y; Kim E; Gao Y; Rankin GO; Li B; Chen YC Int J Oncol; 2016 Jun; 48(6):2657-65. PubMed ID: 27082635 [TBL] [Abstract][Full Text] [Related]
14. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells. Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628 [TBL] [Abstract][Full Text] [Related]
15. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway. Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322 [TBL] [Abstract][Full Text] [Related]
16. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional. Lossaint G; Besnard E; Fisher D; Piette J; Dulić V Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626 [TBL] [Abstract][Full Text] [Related]
17. Acetyl-11-keto-β-boswellic acid enhances the cisplatin sensitivity of non-small cell lung cancer cells through cell cycle arrest, apoptosis induction, and autophagy suppression via p21-dependent signaling pathway. Lv M; Zhuang X; Zhang Q; Cheng Y; Wu D; Wang X; Qiao T Cell Biol Toxicol; 2021 Apr; 37(2):209-228. PubMed ID: 32562082 [TBL] [Abstract][Full Text] [Related]
18. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells. Zhou W; Wang J; Man WY; Zhang QW; Xu WG Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776 [TBL] [Abstract][Full Text] [Related]
19. NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway. Jayachandran G; Ueda K; Wang B; Roth JA; Ji L PLoS One; 2010 Aug; 5(8):e11994. PubMed ID: 20700484 [TBL] [Abstract][Full Text] [Related]
20. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer. Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]